{"id":"rtx-treatment","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Transient edema"},{"rate":null,"effect":"Radiation necrosis (delayed)"}]},"_chembl":{"chemblId":"CHEMBL17976","moleculeType":"Small molecule","molecularWeight":"628.72"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"RTX uses robotic-guided radiation delivery to concentrate high doses of ionizing radiation on tumors, vascular malformations, or functional targets while minimizing exposure to surrounding healthy brain tissue. The system employs real-time imaging and automated positioning to achieve precise targeting, making it suitable for both ablative and functional neurosurgical applications.","oneSentence":"RTX is a robotic stereotactic radiosurgery system that delivers highly focused radiation beams to target intracranial lesions with sub-millimeter precision.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:06:21.522Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Intracranial tumors (primary and metastatic)"},{"name":"Arteriovenous malformations"},{"name":"Functional neurosurgical applications"}]},"trialDetails":[{"nctId":"NCT02522611","phase":"PHASE1, PHASE2","title":"Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2026-02-27","conditions":"Intractable Pain, Palliative Care","enrollment":30},{"nctId":"NCT00804154","phase":"PHASE1","title":"Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer","status":"RECRUITING","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","startDate":"2009-08-14","conditions":"Intractable Pain, Palliative Care","enrollment":45},{"nctId":"NCT07491523","phase":"","title":"Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD","status":"RECRUITING","sponsor":"University of Patras","startDate":"2025-06-01","conditions":"SSc-Systemic Sclerosis","enrollment":35},{"nctId":"NCT05248386","phase":"PHASE3","title":"Efficacy and Safety of RTX-GRT7039 in Adult Subjects With Knee Osteoarthritis","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2022-08-26","conditions":"Osteoarthritis","enrollment":469},{"nctId":"NCT05449132","phase":"PHASE3","title":"Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2022-09-26","conditions":"Osteoarthritis","enrollment":466},{"nctId":"NCT07156565","phase":"PHASE1","title":"Actinium Therapy for Late-stage Aggressive Sarcomas","status":"RECRUITING","sponsor":"Ratio Therapeutics, Inc.","startDate":"2025-11-12","conditions":"Advanced Soft Tissue Sarcoma","enrollment":30},{"nctId":"NCT07457944","phase":"","title":"Efficacy and Safety of Different Doses of Rituximab Therapy in Pemphigus Patients","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2019-01-01","conditions":"Pemphigus Disease, Rituximab (RTx)","enrollment":275},{"nctId":"NCT05894512","phase":"","title":"Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy","status":"COMPLETED","sponsor":"Istanbul University","startDate":"2023-06-01","conditions":"Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced, Membranous Nephropathy - THSD7A Induced","enrollment":44},{"nctId":"NCT04761185","phase":"PHASE1","title":"Raltitrexed in HIPEC","status":"COMPLETED","sponsor":"Fudan University","startDate":"2020-09-18","conditions":"Colorectal Cancer, Raltitrexed, HIPEC","enrollment":30},{"nctId":"NCT07416942","phase":"","title":"Omics of Rituximab-resistance","status":"NOT_YET_RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2026-04","conditions":"Membranous Nephropathy","enrollment":120},{"nctId":"NCT02900976","phase":"PHASE2","title":"Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2017-03-22","conditions":"EBV-Related Post-Transplant Lymphoproliferative Disorder, Monomorphic Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder","enrollment":18},{"nctId":"NCT06204315","phase":"PHASE2","title":"Risk Adapted Spinal Cord/Cauda Constraint Relaxation for High-risk Patients With Metastatic Epidural Spinal Cord Compression Undergoing Spine Stereotactic Radiosurgery","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-11-11","conditions":"Spinal Cord, Metastatic Epidural, Spine Stereotactic","enrollment":60},{"nctId":"NCT07349043","phase":"PHASE1","title":"A Prospective, Safety, and Efficacy Clinical Trial of Pressurized Intraperitoneal Aerosol Therapy for Peritoneal Metastasis of Colorectal Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01","conditions":"Peritoneal Metastasis, CRC (Colorectal Cancer)","enrollment":42},{"nctId":"NCT07271368","phase":"NA","title":"EXTERNAL NEGATIVE PRESSURE DURING LISA","status":"NOT_YET_RECRUITING","sponsor":"Charles University, Czech Republic","startDate":"2025-12-22","conditions":"Neonatology","enrollment":25},{"nctId":"NCT05716334","phase":"","title":"Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2021-06-15","conditions":"ANCA-associated Vasculitis, Granulomatosis With Polyangiitis, Microscopic Polyangiitis","enrollment":201},{"nctId":"NCT06186219","phase":"PHASE1","title":"Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2024-04-10","conditions":"Tophaceous Gout","enrollment":2},{"nctId":"NCT07225439","phase":"PHASE1","title":"Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)","status":"NOT_YET_RECRUITING","sponsor":"Paolo Caimi, MD","startDate":"2025-12","conditions":"Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma","enrollment":15},{"nctId":"NCT03426891","phase":"PHASE1","title":"Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-03-16","conditions":"Glioblastoma, Brain Tumor, GBM","enrollment":21},{"nctId":"NCT07071246","phase":"NA","title":"Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2022-08-01","conditions":"Treatment","enrollment":30},{"nctId":"NCT02763319","phase":"PHASE2, PHASE3","title":"A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-11-28","conditions":"Diffuse Large B-cell Lymphoma","enrollment":453},{"nctId":"NCT07051070","phase":"PHASE4","title":"Efficacy and Safety of Rituximab in the Treatment of Anti-Vimentin Antibody-associated Diseases","status":"NOT_YET_RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2025-07-01","conditions":"Anti-Vimentin Antibody-associated Diseases, Meningoencephalomyelitis Associated With Vimentin IgG Autoantibodies","enrollment":40},{"nctId":"NCT04221035","phase":"PHASE3","title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2019-11-05","conditions":"High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy","enrollment":800},{"nctId":"NCT04848493","phase":"","title":"National Project on Vaccines, COVID-19 and Frail Patients","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2021-04-19","conditions":"COVID-19, Solid Tumor, Hematologic Diseases","enrollment":747},{"nctId":"NCT06676631","phase":"PHASE1","title":"NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2025-02-19","conditions":"Refractory Systemic Lupus Erythematosus, Refractory Lupus Nephritis","enrollment":18},{"nctId":"NCT02378298","phase":"PHASE4","title":"Rituximab (RTX) Therapy in Patients With Active TAO","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2011-12","conditions":"Ophthalmopathy, Thyroid-Associated","enrollment":38},{"nctId":"NCT05269667","phase":"PHASE4","title":"A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2022-08-02","conditions":"Neuromyelitis Optica Spectrum Disorder, NMOSD","enrollment":4},{"nctId":"NCT06729684","phase":"NA","title":"Development and Validation of a Personalized Digital Healthcare Model for Managing Side Effects in Breast Cancer Survivors","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2024-11-13","conditions":"Breast Cancer Survivorship, Breast Cancer, Digital Health","enrollment":72},{"nctId":"NCT06680349","phase":"PHASE4","title":"Two Anti-CD20 Regimens for Fibrillary Glomerulonephritis","status":"COMPLETED","sponsor":"University of Turin, Italy","startDate":"2022-12-01","conditions":"Fibrillary Glomerulonephritis","enrollment":21},{"nctId":"NCT03747159","phase":"PHASE3","title":"Synergetic B-cell Immunomodulation in SLE - 2nd Study.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2018-10-01","conditions":"Lupus Erythematosus, Systemic","enrollment":70},{"nctId":"NCT05682196","phase":"PHASE2","title":"Rituximab in Patients With Acute Rheumatic Fever","status":"SUSPENDED","sponsor":"African Academy of Methodology and Statistics","startDate":"2023-01-05","conditions":"Rheumatic Heart Disease in Children","enrollment":234},{"nctId":"NCT05679336","phase":"NA","title":"Rituximab, Cyclophosphamide, and Corticosteroids in Primary Membranous Nephropathy","status":"RECRUITING","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2018-05-01","conditions":"Membranous Nephropathy - PLA2R Induced","enrollment":40},{"nctId":"NCT05067257","phase":"PHASE2","title":"Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer","status":"SUSPENDED","sponsor":"Sorrento Therapeutics, Inc.","startDate":"2025-09","conditions":"Pain, Intractable, Pain Cancer, Pain","enrollment":120},{"nctId":"NCT06190457","phase":"","title":"Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2015-09-30","conditions":"Lymphoma, Non-Hodgkin, Child, Only","enrollment":16},{"nctId":"NCT02957019","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","status":"TERMINATED","sponsor":"Philogen S.p.A.","startDate":"2013-07-31","conditions":"Diffuse Large B-cell Lymphoma (DLBCL)","enrollment":6},{"nctId":"NCT05969522","phase":"PHASE4","title":"Stratified Therapy on Pediatric AAGN","status":"UNKNOWN","sponsor":"Wang Mo","startDate":"2023-01-01","conditions":"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, ANCA-Associated Glomerulonephritis","enrollment":200},{"nctId":"NCT05861297","phase":"PHASE4","title":"Immune Thrombocytopenia Management in Adults","status":"UNKNOWN","sponsor":"Nahda University","startDate":"2020-05-05","conditions":"Immune Thrombocytopenia Purpura","enrollment":467},{"nctId":"NCT05824390","phase":"PHASE4","title":"A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy","status":"UNKNOWN","sponsor":"XIEJINGYUAN","startDate":"2020-06-20","conditions":"IgA Nephropathy","enrollment":116},{"nctId":"NCT03737968","phase":"PHASE2","title":"Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2019-01-02","conditions":"Stage II-IVB Operable HNSCC Oral Cavity, Hypopharynx, Oropharynx","enrollment":48},{"nctId":"NCT04885972","phase":"PHASE2","title":"Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis","status":"UNKNOWN","sponsor":"Sorrento Therapeutics, Inc.","startDate":"2021-11-15","conditions":"Osteoarthritis, Knee, Knee Osteoarthritis, Knee Pain Chronic","enrollment":124},{"nctId":"NCT04585152","phase":"PHASE2","title":"Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Idiopathic Nephrotic Syndrome.","status":"UNKNOWN","sponsor":"Istituto Giannina Gaslini","startDate":"2020-10-15","conditions":"Nephrotic Syndrome Steroid-Dependent","enrollment":160},{"nctId":"NCT05644210","phase":"","title":"Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2022-10-01","conditions":"Antiphospholipid Syndrome","enrollment":80},{"nctId":"NCT05553496","phase":"PHASE2, PHASE3","title":"Assessment of Rituximab Therapeutic Response Versus Conventional Treatment","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2022-09-25","conditions":"Pharmacological Action","enrollment":40},{"nctId":"NCT04572776","phase":"PHASE3","title":"Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain","status":"WITHDRAWN","sponsor":"Sorrento Therapeutics, Inc.","startDate":"2020-12","conditions":"Pain, Intractable, Pain Cancer","enrollment":""},{"nctId":"NCT04044742","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of Resiniferatoxin for Pain Due to Osteoarthritis of the Knee","status":"WITHDRAWN","sponsor":"Sorrento Therapeutics, Inc.","startDate":"2020-12","conditions":"Osteoarthritis, Knee, Knee Pain Chronic","enrollment":""},{"nctId":"NCT01757288","phase":"PHASE1, PHASE2","title":"Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2013-03-25","conditions":"STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER","enrollment":98},{"nctId":"NCT03542838","phase":"PHASE1","title":"Study of Resiniferatoxin for Knee Pain in Moderate to Severe Osteoarthritis","status":"COMPLETED","sponsor":"Sorrento Therapeutics, Inc.","startDate":"2018-07-12","conditions":"Osteoarthritis, Knee, Pain, Knee","enrollment":94},{"nctId":"NCT03083613","phase":"PHASE2","title":"Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2015-05","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":41},{"nctId":"NCT04127747","phase":"PHASE4","title":"Efficacy of Individualized Rituximab in Maintaining Remission of Moderate and Severe Systemic Lupus Erythematosus","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-08-18","conditions":"Autoimmune Diseases","enrollment":110},{"nctId":"NCT02383589","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-05-26","conditions":"Pemphigus Vulgaris","enrollment":135},{"nctId":"NCT03226574","phase":"PHASE1","title":"Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain","status":"COMPLETED","sponsor":"Sorrento Therapeutics, Inc.","startDate":"2017-09-01","conditions":"Intractable Cancer Pain","enrollment":17},{"nctId":"NCT00671645","phase":"PHASE2","title":"Preoperative Combined RadioChemo-Molecular Target Therapy With Capecitabine, Bevacizumab, and Radiotherapy","status":"TERMINATED","sponsor":"Austrian Breast & Colorectal Cancer Study Group","startDate":"2008-07","conditions":"Rectal Cancer","enrollment":8},{"nctId":"NCT04402580","phase":"PHASE2","title":"Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome","status":"TERMINATED","sponsor":"Istituto Giannina Gaslini","startDate":"2019-07-01","conditions":"Nephrotic Syndrome Steroid-Dependent","enrollment":30},{"nctId":"NCT02236936","phase":"PHASE3","title":"Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck","status":"TERMINATED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2017-02-03","conditions":"Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV, Laryngeal Squamous Cell Carcinoma Stage III","enrollment":8},{"nctId":"NCT02789397","phase":"PHASE2","title":"Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variable Immunodeficiency","status":"WITHDRAWN","sponsor":"Medical College of Wisconsin","startDate":"2016-05-02","conditions":"Granulomatous and Lymphocytic Interstitial Lung Disease","enrollment":""},{"nctId":"NCT01691898","phase":"PHASE1, PHASE2","title":"A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2012-09-27","conditions":"Follicular Lymphoma, Diffuse Large B-Cell Lymphoma","enrollment":231},{"nctId":"NCT01136395","phase":"PHASE2","title":"Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation","status":"COMPLETED","sponsor":"University of Giessen","startDate":"2010-01","conditions":"Kidney Transplantation, Rituximab (RTx), Living Donors","enrollment":85},{"nctId":"NCT01180036","phase":"PHASE2, PHASE3","title":"MEmbranous Nephropathy Trial Of Rituximab","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2011-11","conditions":"Idiopathic Membranous Nephropathy","enrollment":130},{"nctId":"NCT01777750","phase":"NA","title":"Cooling in Myocardial Infarction","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2013-02","conditions":"ST-elevation Myocardial Infarction","enrollment":120},{"nctId":"NCT01181401","phase":"PHASE2","title":"InductionChemo-Radio-Antibody-Treatment","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2010-08","conditions":"Squamous Cell Carcinoma of the Head, Squamous Cell Carcinoma of the Neck","enrollment":94},{"nctId":"NCT02871869","phase":"PHASE2, PHASE3","title":"Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma","status":"UNKNOWN","sponsor":"Xinjiang Medical University","startDate":"2016-09","conditions":"Diffuse, Large B-Cell, Lymphoma","enrollment":316},{"nctId":"NCT00366418","phase":"PHASE1","title":"Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2006-08-10","conditions":"Refractory Chronic Lymphocytic Leukemia","enrollment":4},{"nctId":"NCT03171116","phase":"","title":"Ghrelin and Obestatin in CKD Children","status":"COMPLETED","sponsor":"Azienda Ospedaliero Universitaria Maggiore della Carita","startDate":"2013-01-01","conditions":"Chronic Kidney Diseases","enrollment":154},{"nctId":"NCT00813943","phase":"PHASE2","title":"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2009-03","conditions":"Glioblastoma","enrollment":265},{"nctId":"NCT02966717","phase":"PHASE2","title":"Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2016-08","conditions":"Renal Insufficiency, Chronic, Nephrotic Syndrome","enrollment":116},{"nctId":"NCT02834468","phase":"PHASE3","title":"DEX Combined With RTX, CSA and IVIG in the Management of Newly Diagnosed ITP Patients","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2016-06","conditions":"Immune Thrombocytopenia","enrollment":100},{"nctId":"NCT02731560","phase":"PHASE4","title":"Rituximab (RTX) for Disease Modifying Anti Rheumatic Drug (DMARD) Non-responders in Pakistan: The Pakistan Rituximab Study (PARIS)","status":"COMPLETED","sponsor":"Prof. Abid Z. Farooqi","startDate":"2010-01","conditions":"Rheumatoid Arthritis","enrollment":74},{"nctId":"NCT01332994","phase":"PHASE3","title":"A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-03","conditions":"Rheumatoid Arthritis","enrollment":519},{"nctId":"NCT01673295","phase":"PHASE3","title":"RING - Rituximab for Lupus Nephritis With Remission as a Goal","status":"UNKNOWN","sponsor":"Frédéric A. Houssiau, MD, PhD","startDate":"2014-11","conditions":"Lupus Nephritis","enrollment":194},{"nctId":"NCT01989858","phase":"PHASE3","title":"ITACA-S2 (Intergroup Trial in Adjuvant Chemotherapy for Adenocarcinoma of the Stomach)","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2010-11","conditions":"Gastric Adenocarcinoma","enrollment":1180},{"nctId":"NCT01379261","phase":"PHASE2, PHASE3","title":"Efficacy of Endovascular Catheter Cooling Combined With Cold Saline for the Treatment of Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Region Skane","startDate":"2011-06","conditions":"Myocardial Infarction, Myocardial Reperfusion Injury, Anterior Wall Myocardial Infarction","enrollment":120},{"nctId":"NCT00689221","phase":"PHASE3","title":"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2008-09","conditions":"Glioblastoma","enrollment":545},{"nctId":"NCT01434147","phase":"PHASE2","title":"Preoperative Combined Induction Chemotherapy With Capecitabine, Oxaliplatin, Bevacizumab and Radiotherapy","status":"COMPLETED","sponsor":"Austrian Breast & Colorectal Cancer Study Group","startDate":"2011-10","conditions":"Rectal Cancer","enrollment":25},{"nctId":"NCT01558687","phase":"PHASE1","title":"Cilengitide Imaging Trial in Glioblastoma","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2012-08","conditions":"Supratentorial Newly Diagnosed Inoperable Gliobastoma","enrollment":1},{"nctId":"NCT01706393","phase":"NA","title":"Effects of Probiotics Supplementation on Intestinal Microbiome in Malignancy Pts(Get Pelvic/Abdominal Rtx)","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2012-10","conditions":"Cancer","enrollment":26},{"nctId":"NCT00892827","phase":"PHASE2","title":"Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic Leukemia","status":"UNKNOWN","sponsor":"Wolfson Medical Center","startDate":"2009-04","conditions":"Advanced Refractory Chronic Lymphocytic Leukemia","enrollment":10},{"nctId":"NCT00908505","phase":"NA","title":"Comparison Between RTX (Biphasic Cuirass Ventilator) and Physiotherapy in Cystic Fibrosis Patients","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2009-07","conditions":"Cystic Fibrosis","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":496,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"RTX treatment","genericName":"RTX treatment","companyName":"Xuanwu Hospital, Beijing","companyId":"xuanwu-hospital-beijing","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RTX is a robotic stereotactic radiosurgery system that delivers highly focused radiation beams to target intracranial lesions with sub-millimeter precision. Used for Intracranial tumors (primary and metastatic), Arteriovenous malformations, Functional neurosurgical applications.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}